# GLP-1 pipeline 2026: every drug in phase 2 and 3

Source: https://pepvault.app/guides/glp-1-pipeline

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish

Reviewed November 2026 42 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Every GLP-1-family drug in phase 2 or 3 as of November 20, 2026: company, how it works, its key trial and the ClinicalTrials.gov completion date.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 42
- **Questions:** 9
- **Compounds:** 15

## The short answer

By our count, 16 drugs built on GLP-1 or its partner hormones are in phase 2 or 3 for weight or liver disease as of November 20, 2026. Per ClinicalTrials.gov, the next big trials to finish their main measurement are retatrutide against tirzepatide (TRIUMPH-5, November 2026, estimated) and Amgen's monthly MariTide (January 21, 2027). CagriSema is closest to approval: Novo expects an FDA decision in Q4 2026.

- Retatrutide and CagriSema lead: Lilly plans to file retatrutide in Q1 2027, and Novo expects a CagriSema decision in Q4 2026.
- Three shots given once a month or every four weeks (MariTide, berobenatide and China's zovaglutide) and two new pills, aleniglipron and the zenagamtide tablet, are in phase 3.
- Amylin on its own (cagrilintide, eloralintide, petrelintide) is the newest class; the first phase 3 trial of it, cagrilintide's RENEW 1, reaches primary completion in May 2027 (estimated).
- A primary completion date is when the last measurement is taken, not when results come out.

Every number checked at its primary source · Nov 20, 2026 · [42 sources](https://pepvault.app/guides/glp-1-pipeline#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Registry records and phase 2 and 3 trial results. None of the 16 drugs in the main table is approved by the FDA as of November 20, 2026 (mazdutide is approved in China); dates marked estimated are the registry's and can move.

## Which GLP-1 drugs are in phase 2 and 3 right now?

By our count, the table holds every drug in the GLP-1 family with a phase 2 or 3 weight or liver trial on ClinicalTrials.gov, as of November 20, 2026. Each row names one key trial: the one that finishes next, or the main weight trial. Primary completion is the registry's own date for the last participant's main measurement; an "estimated" date can move. A phase 3 trial is the large, final test before a company files for approval (glossary: /glossary/clinical-trial-phases).

| Drug | Company | How it works | Phase | Key trial | Primary completion, per ClinicalTrials.gov | Our page |
| --- | --- | --- | --- | --- | --- | --- |
| Retatrutide | Eli Lilly | Weekly shot on the GIP, GLP-1 and glucagon receptors (a triple agonist)[2](https://pepvault.app/guides/glp-1-pipeline#source-2) | Phase 3; Lilly plans to file in Q1 2027[3](https://pepvault.app/guides/glp-1-pipeline#source-3) | TRIUMPH-5, against tirzepatide, NCT06662383[1](https://pepvault.app/guides/glp-1-pipeline#source-1) | November 2026 (estimated) | /peptides/retatrutide |
| CagriSema | Novo Nordisk | Weekly shot: the amylin analogue cagrilintide plus semaglutide[6](https://pepvault.app/guides/glp-1-pipeline#source-6) | Filed December 2025; Novo expects an FDA decision in Q4 2026[5](https://pepvault.app/guides/glp-1-pipeline#source-5) | NCT07011667, 609 adults[7](https://pepvault.app/guides/glp-1-pipeline#source-7) | March 1, 2027 (estimated) | /peptides/cagrisema |
| Cagrilintide alone | Novo Nordisk | Weekly long-acting amylin analogue, the fullness hormone[9](https://pepvault.app/guides/glp-1-pipeline#source-9) | Phase 3 | RENEW 1, NCT07220642[8](https://pepvault.app/guides/glp-1-pipeline#source-8) | May 11, 2027 (estimated) | /peptides/cagrilintide |
| MariTide (maridebart cafraglutide) | Amgen | Monthly shot: an antibody that blocks the GIP receptor, joined to GLP-1 agonist peptides[4](https://pepvault.app/guides/glp-1-pipeline#source-4) | Phase 3 | MARITIME-1, NCT06858839[10](https://pepvault.app/guides/glp-1-pipeline#source-10) | January 21, 2027 (estimated) | /peptides/maritide |
| Berobenatide (PF-08653944, MET-097) | Pfizer | Ultra-long-acting GLP-1 analogue, tested weekly and monthly[11](https://pepvault.app/guides/glp-1-pipeline#source-11) | Phase 3 | VESPER-4, weekly, NCT07311850[12](https://pepvault.app/guides/glp-1-pipeline#source-12) | September 21, 2027 (estimated) | None yet |
| Zenagamtide (amycretin) | Novo Nordisk | One molecule on the GLP-1, amylin and calcitonin receptors, as a shot and a pill[13](https://pepvault.app/guides/glp-1-pipeline#source-13) | Phase 3 | AMAZE 1, NCT07339423[14](https://pepvault.app/guides/glp-1-pipeline#source-14) | June 26, 2029 (estimated) | /peptides/amycretin |
| Aleniglipron | Structure Therapeutics (trials under its subsidiary Gasherbrum Bio) | Daily pill: a small chemical molecule that works the GLP-1 receptor[15](https://pepvault.app/guides/glp-1-pipeline#source-15) | Phase 3 | ACCOMPLISH-1, NCT07654361[16](https://pepvault.app/guides/glp-1-pipeline#source-16) | September 2028 (estimated) | None yet |
| Survodutide | Boehringer Ingelheim | Weekly shot on the glucagon and GLP-1 receptors[17](https://pepvault.app/guides/glp-1-pipeline#source-17) | Phase 3; SYNCHRONIZE-1 and -2 finished, more weight and liver trials running[18](https://pepvault.app/guides/glp-1-pipeline#source-18) | SYNCHRONIZE-1, NCT06066515 (main weight trial)[18](https://pepvault.app/guides/glp-1-pipeline#source-18) | December 2, 2025 (actual) | /peptides/survodutide |
| VK2735 | Viking Therapeutics | Weekly shot on the GLP-1 and GIP receptors; a pill version is in phase 3 too[19](https://pepvault.app/guides/glp-1-pipeline#source-19) | Phase 3 | VANQUISH 1, NCT07104500[20](https://pepvault.app/guides/glp-1-pipeline#source-20) | July 1, 2027 (estimated) | /peptides/vk2735 |
| Eloralintide | Eli Lilly | Weekly shot on the amylin receptor alone[21](https://pepvault.app/guides/glp-1-pipeline#source-21) | Phase 3 | ENLIGHTEN-1, NCT07321886[22](https://pepvault.app/guides/glp-1-pipeline#source-22) | March 2028 (estimated) | /peptides/eloralintide |
| Petrelintide | Roche (from Zealand Pharma) | Weekly long-acting amylin analogue[23](https://pepvault.app/guides/glp-1-pipeline#source-23) | Phase 3 | ZUPREME-3, NCT07843498[24](https://pepvault.app/guides/glp-1-pipeline#source-24) | December 21, 2028 (estimated) | /peptides/petrelintide |
| Mazdutide | Innovent Biologics | Weekly shot on the GLP-1 and glucagon receptors[25](https://pepvault.app/guides/glp-1-pipeline#source-25) | Approved in China for weight since June 2025; phase 3 in fatty liver[41](https://pepvault.app/guides/glp-1-pipeline#source-41) | GLORY-3, against semaglutide in fatty liver, China, NCT06884293[26](https://pepvault.app/guides/glp-1-pipeline#source-26) | December 31, 2026 (estimated) | /peptides/mazdutide |
| Pemvidutide | Altimmune | Weekly shot on the glucagon and GLP-1 receptors, tested for MASH, the inflamed fatty liver[27](https://pepvault.app/guides/glp-1-pipeline#source-27) | Phase 3 | PERFORMA, NCT07795164[28](https://pepvault.app/guides/glp-1-pipeline#source-28) | December 2028 (estimated) | /peptides/pemvidutide |
| Ribupatide (HRS9531) | Fujian Shengdi Pharmaceutical | Weekly shot on the GLP-1 and GIP receptors[29](https://pepvault.app/guides/glp-1-pipeline#source-29) | Phase 3, China | Against semaglutide, NCT07285902[30](https://pepvault.app/guides/glp-1-pipeline#source-30) | March 2027 (estimated) | None yet |
| Zovaglutide | Beijing QL Biopharmaceutical | A shot every four weeks; the registry does not name its target[31](https://pepvault.app/guides/glp-1-pipeline#source-31) | Phase 3, China | HORIZON-1, NCT07230119[31](https://pepvault.app/guides/glp-1-pipeline#source-31) | May 29, 2027 (estimated) | None yet |
| Olatorepatide | Regeneron (licensed from Hansoh Pharma, which calls it HS-20094) | A shot on the GLP-1 and GIP receptors[42](https://pepvault.app/guides/glp-1-pipeline#source-42) | Phase 2; phase 3 RISE-1 not yet recruiting[33](https://pepvault.app/guides/glp-1-pipeline#source-33) | NCT07431086, 120 adults[32](https://pepvault.app/guides/glp-1-pipeline#source-32) | November 13, 2026 (estimated; the date has passed and no result is posted) | None yet |

<!--promo-->

If one of these drugs reaches you, through a trial or a prescription, PepVault logs each dose, your side effects and your weight, and builds a report you can bring to your prescriber. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-glp-1-pipeline-inline&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

If one of these drugs reaches you, through a trial or a prescription, PepVault logs each dose, your side effects and your weight, and builds a report you can bring to your prescriber.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What reads out next, in date order?

These are the registry's primary completion dates for the next six months (estimates, and they can move), plus the two meetings where obesity data usually appears. A primary completion is the last main measurement, not a result: results tend to follow by weeks to months, often as a company press release first.

| Date (primary completion unless a meeting) | What | Drug |
| --- | --- | --- |
| November 2026 | TRIUMPH-5, about 800 adults, against tirzepatide[1](https://pepvault.app/guides/glp-1-pipeline#source-1) | Retatrutide |
| November 13, 2026 (passed, no result posted) | Phase 2, 120 adults[32](https://pepvault.app/guides/glp-1-pipeline#source-32) | Olatorepatide |
| December 31, 2026 | GLORY-3, phase 3 against semaglutide in fatty liver, China[26](https://pepvault.app/guides/glp-1-pipeline#source-26) | Mazdutide |
| January 21, 2027 | MARITIME-1 (3,853 adults) and MARITIME-2 (1,105, with type 2 diabetes)[10](https://pepvault.app/guides/glp-1-pipeline#source-10) | MariTide |
| March 1, 2027 | Phase 3 weight trial, 609 adults[7](https://pepvault.app/guides/glp-1-pipeline#source-7) | CagriSema |
| March 2027 | Phase 3 against semaglutide, 572 adults[30](https://pepvault.app/guides/glp-1-pipeline#source-30) | Ribupatide |
| May 11, 2027 | RENEW 1, 300 adults[8](https://pepvault.app/guides/glp-1-pipeline#source-8) | Cagrilintide alone |
| May 18 to 21, 2027 | European Congress on Obesity, Munich[34](https://pepvault.app/guides/glp-1-pipeline#source-34) | Many |
| June 18 to 21, 2027 | American Diabetes Association Scientific Sessions, Washington, D.C.[35](https://pepvault.app/guides/glp-1-pipeline#source-35) | Many |

## Is retatrutide better than tirzepatide?

That is the question TRIUMPH-5 answers, and it is the pipeline's next big moment. Retatrutide's main phase 3 weight trial, TRIUMPH-1, set the bar: 25.0% average weight loss on 12 mg at 80 weeks, against 3.9% on placebo, counting everyone who started[2](https://pepvault.app/guides/glp-1-pipeline#source-2). The head-to-head's design and the numbers it has to beat are in our guide TRIUMPH-5 results (/guides/triumph-5-results); the filing and the FDA clock are in When will retatrutide be approved? (/guides/when-will-retatrutide-be-approved).

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 4 studies](https://pepvault.app/research#cagrisema)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [FDA approval](https://pepvault.app/glossary/fda-approval)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)
- [MASH](https://pepvault.app/glossary/mash)

## When will CagriSema be approved?

CagriSema is the pipeline drug nearest the pharmacy. Novo filed it with the FDA in December 2025 for 2.4 mg of each drug and, on November 14, 2026, still expected a decision in Q4 2026; it is not approved in the US[5](https://pepvault.app/guides/glp-1-pipeline#source-5). In REDEFINE 1, weight fell 20.4% at 68 weeks, against 3.0% on placebo[6](https://pepvault.app/guides/glp-1-pipeline#source-6). The decision, the doses and the label to expect are in CagriSema FDA approval (/guides/cagrisema-fda-decision); what amylin adds is in Cagrilintide and CagriSema (/guides/cagrilintide-and-cagrisema); and the side-by-side with Zepbound and Wegovy is in its own guide (/guides/cagrisema-vs-zepbound-vs-wegovy).

## Is there a monthly GLP-1 shot coming?

Three are in phase 3. MariTide works differently from every approved drug: it switches the GLP-1 receptor on and blocks the GIP receptor, and in phase 2 weight fell 12.3% to 16.2% at 52 weeks, against 2.5% on placebo[4](https://pepvault.app/guides/glp-1-pipeline#source-4). Pfizer's berobenatide runs phase 3 trials both weekly and monthly[12](https://pepvault.app/guides/glp-1-pipeline#source-12), and Beijing QL's zovaglutide, a shot every four weeks, is in phase 3 in China[31](https://pepvault.app/guides/glp-1-pipeline#source-31). MariTide and berobenatide are compared in Is there a monthly GLP-1 shot? (/guides/monthly-glp-1-shots), berobenatide has its own guide (/guides/berobenatide-explained), and the bar MARITIME-1 must clear is in MariTide phase 3 results (/guides/maritime-1-results).

## Which GLP-1 pills are coming?

Aleniglipron is a once-daily pill made of a small chemical molecule rather than a peptide; in its phase 2b trial, weight fell up to 11.3% more than on placebo at 36 weeks[15](https://pepvault.app/guides/glp-1-pipeline#source-15). Novo's zenagamtide is in phase 3 as a daily tablet as well as a weekly shot[13](https://pepvault.app/guides/glp-1-pipeline#source-13). Aleniglipron and its trial switching people from shots to the pill are in our aleniglipron guide (/guides/aleniglipron-switch-trial). Two pills have already left the pipeline, covered below.

## What does amylin add, and who is testing it?

Amylin is a fullness hormone the pancreas releases with insulin, and it is the pipeline's newest class[9](https://pepvault.app/guides/glp-1-pipeline#source-9). Three companies test it alone: Novo's cagrilintide, Lilly's eloralintide and Roche's petrelintide. Eloralintide alone cut weight by up to 20% at 48 weeks in phase 2, against 0.4% on placebo, among people who stayed on treatment[21](https://pepvault.app/guides/glp-1-pipeline#source-21). Petrelintide cut 7.9% to 9.8% at 28 weeks, against 1.7% on placebo, also among people on treatment[23](https://pepvault.app/guides/glp-1-pipeline#source-23). The first phase 3 trial of amylin alone to finish is cagrilintide's RENEW 1, with primary completion estimated for May 11, 2027[8](https://pepvault.app/guides/glp-1-pipeline#source-8). All three, with zenagamtide, are side by side in The amylin drugs in trials (/guides/amylin-drugs-in-trials).

## Which drugs already left the pipeline?

- **The Wegovy pill** (semaglutide tablets), FDA approved December 22, 2025[36](https://pepvault.app/guides/glp-1-pipeline#source-36). Our guide: The Wegovy pill (/guides/the-wegovy-pill).
- **Foundayo** (orforglipron), Lilly's daily pill, FDA approved April 1, 2026[37](https://pepvault.app/guides/glp-1-pipeline#source-37). In its main trial, weight fell 11.2% at the top trial dose at 72 weeks, against 2.1% on placebo[38](https://pepvault.app/guides/glp-1-pipeline#source-38). Lilly is still running phase 3 trials in other groups, such as people with type 2 diabetes (NCT06972472, primary completion August 2027)[39](https://pepvault.app/guides/glp-1-pipeline#source-39). Our guide: Foundayo vs the shots (/guides/foundayo-vs-the-shots).
- **Ecnoglutide** (Sciwind), approved in China for weight in March 2026; it is not approved in the US[40](https://pepvault.app/guides/glp-1-pipeline#source-40).

Mazdutide is approved in China too, but stays in the table above for its phase 3 liver trial[41](https://pepvault.app/guides/glp-1-pipeline#source-41). The approved brands, side by side, are on our drugs page (/drugs). Regeneron's olatorepatide, the newest name in the table, has its own guide (/guides/olatorepatide-explained).

## How do you check a trial date yourself?

Dates in this table move, so here is how to read one at the source. It takes about a minute.

1. Open clinicaltrials.gov/study/ followed by the trial's NCT number, for example clinicaltrials.gov/study/NCT06662383.
2. Read the sponsor under "Sponsor": it should be the company that owns the drug or its named subsidiary. A sponsor you cannot match to the drug's owner is a reason to doubt the record.
3. Find "Primary Completion" in the study details, and note whether it says "Estimated" or "Actual".
4. Check "Last Update Posted": an estimate updated last month is worth more than one untouched for a year.
5. Look for a "Results posted" tab. Do not expect it on the day: results usually come first as a company press release or a conference talk, and reach the registry later.

<!--promo-->

If you are in one of these trials, PepVault can keep your own record next to it: each dose as you logged it, your weekly weigh-ins and the side effects you noted. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-glp-1-pipeline-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. ClinicalTrials.gov NCT06662383 (TRIUMPH-5), Eli Lilly; read at the v2 API Nov 20, 2026 [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662383)
2. Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026;395:1781-1793. [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3); plans to submit in Q1 2027. Press release, July 23, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html)
4. Jastreboff AM et al. Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial. N Engl J Med. 2025. [PubMed 40549887](https://pubmed.ncbi.nlm.nih.gov/40549887/)
5. Novo Nordisk. CagriSema demonstrated approx. 21% average weight loss (REDEFINE 9). Company announcement, Nov 14, 2026. [novonordisk.com](https://www.novonordisk.com/news-and-media/news-and-ir-materials/cagrisema-a-glp-1-and-amylin-analogue-demonstrated-approx-21-percent-average-weight-loss.html)
6. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393:635-647. [PubMed 40544433](https://pubmed.ncbi.nlm.nih.gov/40544433/)
7. ClinicalTrials.gov NCT07011667 (CagriSema, 609 adults), Novo Nordisk [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011667)
8. ClinicalTrials.gov NCT07220642 (RENEW 1, cagrilintide), Novo Nordisk [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220642)
9. Lau DCW et al. Once-weekly cagrilintide for weight management: a phase 2 trial. Lancet. 2021. [PubMed 34798060](https://pubmed.ncbi.nlm.nih.gov/34798060/)
10. ClinicalTrials.gov NCT06858839 (MARITIME-1) and NCT06858878 (MARITIME-2), Amgen [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858839)
11. ClinicalTrials.gov NCT06712836 (VESPER-1, MET097), Pfizer: intervention description [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712836)
12. ClinicalTrials.gov NCT07311850 (VESPER-4, weekly), Pfizer; also NCT07595549 (VESPER-6, once-monthly PF-08653944) [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07311850)
13. Mora et al. Once-weekly subcutaneous zenagamtide in type 2 diabetes: a phase 2 trial. Lancet. 2026; and AMAZE 9 (NCT07720271, zenagamtide tablets). [PubMed 42532080](https://pubmed.ncbi.nlm.nih.gov/42532080/)
14. ClinicalTrials.gov NCT07339423 (AMAZE 1), Novo Nordisk [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339423)
15. Rosenstock J et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a phase 2b trial. Nat Med. 2026. [PubMed 42249138](https://pubmed.ncbi.nlm.nih.gov/42249138/)
16. ClinicalTrials.gov NCT07654361 (ACCOMPLISH-1), Gasherbrum Bio, a wholly owned subsidiary of Structure Therapeutics [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654361)
17. Wharton S et al. Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2). N Engl J Med. 2026. [PubMed 42820639](https://pubmed.ncbi.nlm.nih.gov/42820639/)
18. ClinicalTrials.gov NCT06066515 (SYNCHRONIZE-1) and NCT06066528 (SYNCHRONIZE-2), both completed; running phase 3: NCT07850050, NCT07855900 (weight), NCT06632457 (MASH cirrhosis); Boehringer Ingelheim [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06066515)
19. Bays H et al. Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist: phase 2 VENTURE study. Obesity. 2026; and SUNRISE 1 (NCT07868835, oral VK2735). [PubMed 41508550](https://pubmed.ncbi.nlm.nih.gov/41508550/)
20. ClinicalTrials.gov NCT07104500 (VANQUISH 1), Viking Therapeutics [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104500)
21. Billings LK et al. Eloralintide, a selective amylin receptor agonist: a 48-week phase 2 trial. Lancet. 2025. [PubMed 41207310](https://pubmed.ncbi.nlm.nih.gov/41207310/)
22. ClinicalTrials.gov NCT07321886 (ENLIGHTEN-1), Eli Lilly [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321886)
23. Garvey WT et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a phase 2 trial. Lancet Diabetes Endocrinol. 2026. [PubMed 42810355](https://pubmed.ncbi.nlm.nih.gov/42810355/)
24. ClinicalTrials.gov NCT07843498 (ZUPREME-3), Hoffmann-La Roche [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843498)
25. Ji L et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med. 2025. [PubMed 40421736](https://pubmed.ncbi.nlm.nih.gov/40421736/)
26. ClinicalTrials.gov NCT06884293 (IBI362 vs semaglutide), Innovent Biologics [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06884293)
27. Noureddin M et al. Weekly pemvidutide versus placebo for MASH (IMPACT): 48-week results. Lancet Gastroenterol Hepatol. 2026. [PubMed 43014327](https://pubmed.ncbi.nlm.nih.gov/43014327/)
28. ClinicalTrials.gov NCT07795164 (PERFORMA), Altimmune [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795164)
29. He et al. Preclinical and first-in-human evaluation of ribupatide (HRS9531), a dual GLP-1/GIP receptor agonist. Diabetes Obes Metab. 2026. [PubMed 42764407](https://pubmed.ncbi.nlm.nih.gov/42764407/)
30. ClinicalTrials.gov NCT07285902 (HRS9531 vs semaglutide), Fujian Shengdi Pharmaceutical [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285902)
31. ClinicalTrials.gov NCT07230119 (zovaglutide, HORIZON-1), Beijing QL Biopharmaceutical [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230119)
32. ClinicalTrials.gov NCT07431086 (olatorepatide phase 2), Regeneron [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431086)
33. ClinicalTrials.gov NCT07896265 (RISE-1, olatorepatide phase 3), Regeneron [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896265)
34. European Congress on Obesity 2027, Munich, 18-21 May 2027 (congress site) [eco2027.org](https://eco2027.org/)
35. American Diabetes Association. Scientific Sessions, June 18-21, 2027, Washington, D.C. [professional.diabetes.org](https://professional.diabetes.org/scientific-sessions)
36. Drugs@FDA. NDA 218316, Wegovy (semaglutide) tablets: original approval Dec 22, 2025. [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316)
37. Drugs@FDA. NDA 220934, Foundayo (orforglipron): original approval Apr 1, 2026. [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934)
38. Wharton S et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025. [PubMed 40960239](https://pubmed.ncbi.nlm.nih.gov/40960239/)
39. ClinicalTrials.gov NCT06972472 (orforglipron in obesity and type 2 diabetes), Eli Lilly [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06972472)
40. Shirley M. Ecnoglutide: first approvals. Drugs. 2026. [PubMed 42412371](https://pubmed.ncbi.nlm.nih.gov/42412371/)
41. Shirley M. Mazdutide: first approval. Drugs. 2025;85:1621-1627. [PubMed 41028652](https://pubmed.ncbi.nlm.nih.gov/41028652/)
42. Hansoh Pharma. Hansoh Pharma grants Regeneron an exclusive license to its investigational dual GLP-1/GIP receptor agonist HS-20094. Press release, June 2, 2025. [hansoh.cn](https://www.hansoh.cn/en/news/news-detail-513935.htm)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)

No monthly GLP-1 shot is approved yet. MariTide and berobenatide are in phase 3: how one shot lasts a month, what phase 2 found, and when results are due.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [CagriSema Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrisema)
- [Cagrilintide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrilintide)
- [MariTide Studied range: 21–420 mg](https://pepvault.app/peptides/maritide)
- [Amycretin Studied range: 0.4–60 mg](https://pepvault.app/peptides/amycretin)
- [Survodutide Studied range: 0.3–6 mg](https://pepvault.app/peptides/survodutide)
- [VK2735 Studied range: 2.5–17.5 mg](https://pepvault.app/peptides/vk2735)
- [Eloralintide Studied range: 1–9 mg](https://pepvault.app/peptides/eloralintide)
- [Petrelintide Studied range: 1–9 mg](https://pepvault.app/peptides/petrelintide)
- [Mazdutide Studied range: 2–6 mg](https://pepvault.app/peptides/mazdutide)
- [Pemvidutide Studied range: 1.2–2.4 mg](https://pepvault.app/peptides/pemvidutide)
- [Orforglipron Studied range: 0.8–17.2 mg](https://pepvault.app/peptides/orforglipron)
- [Ecnoglutide Studied range: 0.6–2.4 mg](https://pepvault.app/peptides/ecnoglutide)
- [Semaglutide (oral) Studied range: 1.5–25 mg](https://pepvault.app/peptides/semaglutide-oral)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)

  TRIUMPH-5 puts retatrutide against tirzepatide in about 800 adults. What it tests, the numbers to beat, when it should report and how to read the result.

  Read the guide
- Guide · GLP-1s

  ### [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)

  CagriSema is not FDA approved yet (Nov 20, 2026); Novo expects a decision in Q4 2026. The dose it filed, the warnings to expect and five trials' numbers.

  Read the guide
- Guide · GLP-1s

  ### [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)

  No monthly GLP-1 shot is approved yet. MariTide and berobenatide are in phase 3: how one shot lasts a month, what phase 2 found, and when results are due.

  Read the guide
- Guide · GLP-1s

  ### [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)

  MariTide's phase 3 MARITIME-1 trial: what it tests, what phase 2 showed, the bar Zepbound and Wegovy set, and when the 72-week results are expected.

  Read the guide
- Guide · GLP-1s

  ### [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)

  Retatrutide isn't approved yet. Lilly plans to file with the FDA in early 2027. The review clock, the phase 3 dates and the court case, as of November 2026.

  Read the guide
- Guide · GLP-1s

  ### [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)

  Aleniglipron is Structure Therapeutics' daily GLP-1 pill in testing: its phase 2 numbers, every trial, and what its shot-to-pill SWITCH trial must beat.

  Read the guide
- Guide · GLP-1s

  ### [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)

  Foundayo (orforglipron) is a daily GLP-1 pill, not a peptide. Its ATTAIN and ACHIEVE results beside Zepbound's SURMOUNT and Wegovy's STEP, in one table.

  Read the guide
- Guide · GLP-1s

  ### [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)

  The Wegovy pill is daily semaglutide, FDA approved in December 2025. How to take it, its doses beside the weekly shot's, and OASIS 4 next to STEP 1.

  Read the guide
- Guide · GLP-1s

  ### [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)

  Cagrilintide is a weekly amylin drug, not a GLP-1. What it did alone, what it added to semaglutide in CagriSema's trials, the side effects and FDA status.

  Read the guide
- Guide · GLP-1s

  ### [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)

  Berobenatide (PF-08653944, MET-097i) is Pfizer's monthly GLP-1 shot in phase 3: how it lasts, every phase 2 number, all 24 trials, and when results are due.

  Read the guide
- Guide · GLP-1s

  ### [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)

  Olatorepatide (HS-20094) is a weekly GLP-1/GIP shot from Hansoh, licensed to Regeneron: the 19.3% phase 3 result, every trial, and when US data is due.

  Read the guide
- Guide · GLP-1s

  ### [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)

  Eloralintide, petrelintide and amycretin side by side: the doses their trials used, weight loss vs placebo, side effects and phase 3 status as of Nov 2026.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 4 studies](https://pepvault.app/research#cagrisema)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [FDA approval](https://pepvault.app/glossary/fda-approval)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)
- [MASH](https://pepvault.app/glossary/mash)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
